Corpus Intelligence DCF — ANMED HEALTH 2026-04-26 02:10 UTC
DCF — ANMED HEALTH
Enterprise Value: $-301.4M
🛡️ Public data only — no PHI permitted on this instance.
$-301.4M
Enterprise Value
$-109.7M
PV of Cash Flows
$-191.7M
PV of Terminal Value
$-308.8M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth

Cash Flow Projections

PROJ
YearRevenueEBITDAMarginFCFPV(FCF)
Year 1$614.6M$-11.0M-2.0%$-37.0M$-33.6M
Year 2$633.0M$-5.0M-1.0%$-31.8M$-26.2M
Year 3$652.0M$1.4M0.0%$-26.2M$-19.7M
Year 4$671.6M$4.8M1.0%$-23.6M$-16.1M
Year 5$691.7M$6.7M1.0%$-22.6M$-14.0M

Interpretation

INT

At a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-301.4M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.

Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.

Assumptions

ASSM
revenue base$596.7M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.022832329518004887
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5